|
Gene: GLS2 |
Gene summary for GLS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GLS2 | Gene ID | 27165 |
Gene name | glutaminase 2 | |
Gene Alias | GA | |
Cytomap | 12q13.3 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A0A087X004 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27165 | GLS2 | P2T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.09e-01 | 0.1177 |
27165 | GLS2 | P4T-E | Human | Esophagus | ESCC | 3.13e-03 | 1.10e-01 | 0.1323 |
27165 | GLS2 | P12T-E | Human | Esophagus | ESCC | 8.40e-04 | 9.81e-02 | 0.1122 |
27165 | GLS2 | P16T-E | Human | Esophagus | ESCC | 3.35e-02 | 3.09e-02 | 0.1153 |
27165 | GLS2 | P23T-E | Human | Esophagus | ESCC | 5.77e-06 | 1.51e-01 | 0.108 |
27165 | GLS2 | P26T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.41e-01 | 0.1276 |
27165 | GLS2 | P27T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.37e-01 | 0.1055 |
27165 | GLS2 | P28T-E | Human | Esophagus | ESCC | 1.78e-03 | 8.39e-02 | 0.1149 |
27165 | GLS2 | P48T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.09e-01 | 0.0959 |
27165 | GLS2 | P52T-E | Human | Esophagus | ESCC | 7.90e-03 | 8.70e-02 | 0.1555 |
27165 | GLS2 | P54T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.38e-01 | 0.0975 |
27165 | GLS2 | P57T-E | Human | Esophagus | ESCC | 7.90e-03 | 7.60e-02 | 0.0926 |
27165 | GLS2 | P74T-E | Human | Esophagus | ESCC | 3.40e-23 | 5.27e-01 | 0.1479 |
27165 | GLS2 | P83T-E | Human | Esophagus | ESCC | 2.98e-08 | 2.12e-01 | 0.1738 |
27165 | GLS2 | P107T-E | Human | Esophagus | ESCC | 2.19e-08 | 9.09e-02 | 0.171 |
27165 | GLS2 | P128T-E | Human | Esophagus | ESCC | 3.62e-17 | 4.66e-01 | 0.1241 |
27165 | GLS2 | P130T-E | Human | Esophagus | ESCC | 1.15e-45 | 8.62e-01 | 0.1676 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00086525 | Esophagus | ESCC | cellular amino acid biosynthetic process | 51/8552 | 76/18723 | 1.30e-04 | 8.88e-04 | 51 |
GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
GO:19016075 | Esophagus | ESCC | alpha-amino acid biosynthetic process | 45/8552 | 68/18723 | 5.13e-04 | 2.84e-03 | 45 |
GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
GO:00436485 | Esophagus | ESCC | dicarboxylic acid metabolic process | 58/8552 | 96/18723 | 2.55e-03 | 1.09e-02 | 58 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLS2 | SNV | Missense_Mutation | c.1727A>T | p.Gln576Leu | p.Q576L | Q9UI32 | protein_coding | tolerated(0.11) | benign(0.065) | TCGA-DM-A282-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GLS2 | SNV | Missense_Mutation | novel | c.1597N>A | p.Glu533Lys | p.E533K | Q9UI32 | protein_coding | tolerated(0.13) | benign(0.086) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | novel | c.1678G>A | p.Ala560Thr | p.A560T | Q9UI32 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | c.1102G>A | p.Ala368Thr | p.A368T | Q9UI32 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
GLS2 | SNV | Missense_Mutation | novel | c.1597N>A | p.Glu533Lys | p.E533K | Q9UI32 | protein_coding | tolerated(0.13) | benign(0.086) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | novel | c.880N>C | p.Tyr294His | p.Y294H | Q9UI32 | protein_coding | tolerated(0.3) | possibly_damaging(0.852) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | rs749070379 | c.319N>T | p.Arg107Trp | p.R107W | Q9UI32 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | rs372757263 | c.1559N>A | p.Arg520His | p.R520H | Q9UI32 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GLS2 | SNV | Missense_Mutation | c.538N>A | p.Ala180Thr | p.A180T | Q9UI32 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GLS2 | SNV | Missense_Mutation | c.480C>A | p.Phe160Leu | p.F160L | Q9UI32 | protein_coding | deleterious(0.02) | benign(0.43) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |